Stronvivo Announces New Nationwide Clinical Study

HOUSTON–(BUSINESS WIRE)–Stronvivo, an all-natural, Informed-Choice certified nutritional
supplement shown to improve the sexual functioning of men and women,
will be conducting a series of nationwide clinical studies in concert
with physicians and scientists with the intent of validating additional
claims such as increased energy, improved alertness, and mood elevation.

“While our clinical results have been validated by thousands of patients
and doctors, we’ve discovered that Stronvivo is being used by men and
women not only to improve sexual functioning but also to relieve
symptoms of depression and improve alertness,” says Ron Merrill,
President. “Because medical experts have been recommending Stronvivo to
their patients to help increase the health of blood vessels and improve
circulation, we will be conducting new clinical studies to measure
additional positive changes while continuing to gauge improvements in
sexual function for men who suffer from Borderline Androgen Deficiency,
also known as andropause or male menopause, that affects approximately
half of all men from age 30-80.”

After testosterone and nitric oxide production peak at age 21, both
decrease every year thereafter. By age 55, men and women produce less
than 1/3 of nitric oxide resulting in a decrease in vitality, energy and
endurance. Stronvivo reverses this decline by improving the health of
the endothelium and boosting nitric oxide production. A proprietary
formula of Nitric Oxide precursors has been shown to improve
circulation, reduce platelet aggregation, and support healthy hormone
levels in men and women.

Patients from past and current studies report feeling more alert, having
more energy, feeling younger, sleeping better, feeling less stressed and
less angry, and having meaningful increases in sexual desire, arousal,
performance and functioning within 30 to 60 days of starting Stronvivo
with many users reporting the gains much sooner. Some patients have
reported benefits in heart health such as relief from high blood
pressure and lowing of high cholesterol levels after taking Stronvivo
for two years.

By increasing nitric oxide production, Stronvivo works in conjunction
with and can increase the effects of PDE-5 inhibitors such as Viagra,
Cialis, Stendra and Levitra. Additionally, Stronvivo is designed to
increase testosterone levels by inhibiting the conversion of
testosterone into estradiol and to counteract blood clotting risks by
reducing platelet aggregation and adhesion. Because 54% of men who use
testosterone gels, shots, patches and implants have blood clotting
problems, Stronvivo is a perfect companion to testosterone replacement
therapy.

Stronvivo
plans to enroll at least 6000 men and women into the study, designed to
further test the effectiveness and measurable life improvements received
by Stronvivo users while targeting, mitigating or reversing many of the
typical health changes that come with aging. People who would like to be
considered for participation in the clinical study are invited to
register at clinicalstudy.stronvivo.com.

“I am pleased to recommend Stronvivo to my patients, a natural choice
when it comes to treating decreased sexual functioning,” says Urologist
Laurence Levine, M.D. “For my patients who are suffering with Peyronie’s
disease, I recommend that they take Stronvivo for at least 6 months so
that they can benefit from the amino acids’ presumed anti-fibrotic
qualities along with the libido and erection benefits. Many of my
patients have experienced improvement in erections and libido, likely as
a result of improved and spontaneous erections. I look forward to seeing
the study results.”

Stronvivo
manufactures its products in the USA in an FDA approved, cGMP and USDA
certified facility using only USP Pharmaceutical Grade FDA validated
ingredients.